- Are we justified to classify patients with two unrelated clones with del(5q) and trisomy 8 as a subgroup of myelodysplastic syndrome of the type of 5q-syndrome?2014 | First Faculty of Medicine
- Changes associated with lenalidomide treatment in the gene expression profiles of patients with Del(5q)2012 | First Faculty of Medicine
- Analysis of myelodysplastic syndrome patients with deletion of long arm chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment2009 | Faculty of Medicine in Hradec Králové
- Analysis of myelodysplastic syndrome patients with deletion of long arm chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment2009 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Analysis of myelodysplastic syndrome patients with deletion of long arm chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment2009 | First Faculty of Medicine
- Analysis of myelodysplastic syndrome patients with deletion of long arm of chromosome 5 followed up by the Czech MDS Working Group. Significance for the diagnostic and prognostic assessment2009 | First Faculty of Medicine
- Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide2015 | First Faculty of Medicine
- Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment2015 | First Faculty of Medicine
- Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q)Publication without faculty affiliation
- Klinický význam rozsahu del(5q) u nemocných s MDS2021 | First Faculty of Medicine, Central Library of Charles University
- Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial2018 | First Faculty of Medicine
- Významný recentní přehled o klinice, patogenezi a terapii MDS s del(5q) lenalidomidem2014 | First Faculty of Medicine
- Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion2018 | Publication without faculty affiliation
- Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)2018 | First Faculty of Medicine
- Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS2019 | First Faculty of Medicine
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents2016 | First Faculty of Medicine
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Faculty of Science
- Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome2015 | First Faculty of Medicine
- True monosomy of chromosome 5 is presumably not an isolated cytogenetic entity in MDSPublication without faculty affiliation
- True monozomy of chromosome 5 is presumably not an isolated cytogenetic entity in myelodysplastic syndromes (MDS).Publication without faculty affiliation
- TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes2016 | First Faculty of Medicine
